amoxicillin-potassium-clavulanate-combination and Mastitis

Breast-feeding is considered the gold standard for infant nutrition. In spite of statements about the safe use of drugs in lactation by the American Academy of Pediatrics, medical professionals remain confused regarding the management of drug therapy in nursing mothers, and this can lead to suboptimal prescribing and poor compliance. The aim of our study was to evaluate the safety of 2 of the newer antibiotics, amoxicillin/clavulanic acid and cefuroxime, during lactation. Breast-feeding women who called a drug consultation center to obtain information about the potential risks of amoxicillin/clavulanic acid (67 women) and cefuroxime (38 women) were prospectively recruited. As a control group, women who were treated with antibiotics known to be safe during lactation were recruited: amoxicillin (n = 40) for the amoxicillin/clavulanic acid group and cephalexin (n = 11) for the cefuroxime group. Women in the control group were matched for indication for antibiotic therapy, duration of treatment, and maternal age. Participants were interviewed after treatment termination regarding adverse reactions during therapy. In the amoxicillin/clavulanic acid group, 15 infants (22.3%) had adverse effects, and the rate increased with dosage (P = 0.0139). This was significantly higher than the amoxicillin group, where 3 infants (7.5%) had adverse effects (P = 0.046, relative risk (RR) = 2.99, 95% confidence interval (CI) 0.92-9.68). However, there were no significant differences between rates of specific events. The rate of adverse effects in the cefuroxime group (2.6%) was not significantly different from that in controls (9%) (P = 0.58, OR = 0.92, 95% CI 0.94-1.06). All adverse effects were minor, self-limiting, and did not necessitate interruption of breast-feeding. Our data suggest that amoxicillin/clavulanic acid and cefuroxime may be safe during lactation. Larger studies are needed to confirm these findings.

Topics: Adult; Alanine Transaminase; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aspartate Aminotransferases; Breast Feeding; Cefuroxime; Clavulanic Acid; Diarrhea, Infantile; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Infant; Lactation; Mastitis; Maternal Age; Middle Aged; Prospective Studies; Respiratory Tract Infections

Topics: Abscess; Actinomycetaceae; Actinomycetales Infections; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Combined Modality Therapy; Drainage; Drug Resistance, Microbial; Female; Humans; Immunocompetence; Male; Mastitis; Prostatitis; Scrotum

Mastitis in non-lactating adolescents is rare and its cause unclear. This retrospective study summarizes 22 such episodes, in 3 of which Staphylococcus aureus was isolated. Serum prolactin levels were normal. Most patients were successfully treated with oral amoxicillin-clavulanic acid. Three patients with bilateral breast cysts had a recurrence.

Topics: Administration, Oral; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Breast Cyst; Child; Clindamycin; Female; Floxacillin; Humans; Mastitis; Prolactin; Recurrence; Retrospective Studies; Staphylococcus aureus

Augmentin was used in treatment of mild forms of postnatal endometritis and serous mastitis. Augmentin tablets proved to be efficient in endometritis due to enterobacteria and obligate nonsporulating anaerobes and mastitis due to Staphylococcus aureus strains sensitive to the preparation. No adverse events were recorded. It was shown that in the treatment of mild postnatal infections the augmentin tablets were not inferior by their activity of combinations of antibiotics against aerobic and anaerobic microflora.

Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Endometritis; Female; Humans; Mastitis; Microbial Sensitivity Tests; Puerperal Infection; Tablets

Due to the impact of the dairy quota system, the commercial use of goats for the production of milk and associated products is attractive to farmers diversifying their dairy interest. Intensification of milking and the expansion of herds will inevitably increase the incidence of caprine mastitis. The pharmaceutical industry and the veterinary surgeon will be required to provide data and advice upon the performance of currently available bovine intramammary products when used in the goat. This study produced evidence that one available bovine intramammary product, when infused into the glands of milking goats, produced a withholding time approximately double that defined for the cow. Following a course of infusions after three successive milkings, milk was not available for human consumption or for the production of cheese and yoghurt until 112 hours after the final infusion. This situation is likely to be representative of that which will occur for other currently available bovine intramammaries when prescribed in the goat.

Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Animals; Clavulanic Acids; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Female; Goat Diseases; Goats; Infusions, Parenteral; Lactation; Mammary Glands, Animal; Mastitis; Milk; Prednisolone; Pregnancy